Drug Trial Radar · NCT07213817
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
114
Planned (sponsor's estimate)
Start
Dec 5, 2025
Primary completion
Oct 30, 2028
Study completion Oct 30, 2028
Sponsor
- Lead sponsor
- IpsenIndustry
- Sponsor type
- Industry
- First posted
- Oct 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to find the right dosage and evaluate the safety and effectiveness of the drug IPN60300 in adults with advanced solid tumours, which are cancers that have spread to other parts of the body from their original location. All participants will receive the drug by injection. Study Phases: * Phase Ia: Participants with certain types of tumours will be treated in cohorts of increasingly higher doses of the drug to determine the safe and effective dose range (a high and a low dose). * Phase Ib: Participants with a specific tumour type will receive one of the two doses identified in phase Ia. The dose level will be assigned randomly (by chance). Study Periods: Screening: Up to 28 days before first IPN60300 injection to determine eligibility. Treatment: Starts with the first dose of IPN60300 and continues until it needs to be stopped due to harmful effects, the disease getting worse, or if the participant decides to stop taking part in the study, the investigator's decision to stop treatment, death or the study is terminated early by the sponsor. Participants will undergo blood tests, urine collections, physical examinations, and clinical evaluations.
Conditions
- Locally Advanced Solid Tumor
- Metastatic Solid Tumor
Interventions
IPN60300Biological
IPN60300 will be administered at assigned dose level.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ia: Percentage of participants with dose limiting toxicity (DLT)Time frame: within 21 days following study drug administration.
- Phase Ia and Ib: Percentage of participants experiencing Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TE SAEs).Time frame: From the first IPN60300 administration until 30 days after the last dose
- Phase Ib: Objective response rate (ORR)Time frame: At end of study (up to approximately 3 years )
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
Yale Cancer Center-Yale University
New Haven, Connecticut · Recruiting
START Midwest
Grand Rapids, Michigan · Recruiting
Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Oncology
San Antonio, Texas · Recruiting
NEXT Oncology
Fairfax, Virginia · Recruiting
Centre Leon Berard
Lyon, France · Recruiting
Institut de Cancerologie de l'Ouest (ICO)- CRLCC Rene Gauducheau
Saint-Herblain, France · Recruiting
Gustave Roussy Cancer Campus Grand Paris- (Institut de Cancerologie Gustave-Roussy)
Villejuif, France · Recruiting
Hospital Universitari Vall d'Hebron
Barcelona, Spain · Not yet recruiting
NEXT Quiron-Barcelona
Barcelona, Spain · Active not recruiting
START Madrid CIOCC Hospital Universitario HM Sanchinarro
Madrid, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.